Thrombosis
Conference Coverage
PV: Novel rusfertide shows ‘impressive’ efficacy
The novel synthetic form of liver hormone hepcidin represents a “paradigm shift” in polycythemia vera treatment, allowing patients to avoid the...
From the Journals
Focus of new ASH VTE guidelines: Thrombophilia testing
New guidelines recommend testing for thrombophilia in patients with VTE provoked by a nonsurgical major transient risk factor or associated with...
Feature
Dabigatran recalled over potential carcinogen
The nationwide recall is because of the detection of the nitrosamine impurity, N-nitroso-dabigatran.
Conference Coverage
FREEDOM COVID: Full-dose anticoagulation cut mortality but missed primary endpoint
In an in-hospital anticoagulation trial, the primary COVID endpoint was missed but a survival benefit is observed.
From the Journals
Cardiac issues twice as likely with COVID plus high troponin
Hospitalized COVID-19 patients with high troponin levels were twice as likely to have cardiac abnormalities due to diverse causes in a large U.K....
Latest News
Warfarin best for thrombotic antiphospholipid syndrome?
A vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, appears to be a better treatment for patients with thrombotic...
Conference Coverage
COVID update: ASH experts discuss thrombosis, immunity
Presidential symposium plumbs the mysteries of an “extraordinarily stealthy” virus, considers postvaccine blood clots.
Conference Coverage
ITP: Biologic beat placebo, but few patients improved
Exorbitant efgartigimod meets primary endpoint in only 21.8% of patients with chronic disease.
From the Journals
Statins tied to lower ICH risk regardless of bleed location
A large new case-control study has shown a reduced risk of both lobar and nonlobar intracerebral hemorrhage with statin use, providing reassurance...
Conference Coverage
For minorities with PE: Less advanced treatment, more mortality
Asians/Pacific Islanders with pulmonary embolism faced the lowest risk of hospitalization but died at the highest rate, new study finds.
Conference Coverage
No benefit of rivaroxaban in COVID outpatients: PREVENT-HD
PREVENT-HD joins a long list of smaller trials also showing no benefit of anticoagulation in nonhospitalized COVID-19 patients.